[{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ABV-1701","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ABV-1701","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ABV-1701","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ABV-1701","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ABV-1701","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ABV-1701","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Adipic Dihydrazide

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : ABV-1701 is a hyaluronic acid derived hydrogel therapy which is currently being investigated for the treatment of retinal detachment and vitreous hemorrhage.

                          Product Name : Vitargus

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 04, 2023

                          Lead Product(s) : ABV-1701,Adipic Dihydrazide

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : ABV-1701 is a hyaluronic acid derived hydrogel therapy which is currently being investigated for the treatment of retinal detachment and vitreous hemorrhage.

                          Product Name : Vitargus

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 22, 2023

                          Lead Product(s) : ABV-1701,Adipic Dihydrazide

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Vitargus (hyaluronic acid-derived therapy) is a next-generation vitreous substitute that a First-In-Human clinical trial has demonstrated is a significant upgrade to current vitreous substitutes available to eye surgeons.

                          Product Name : Vitargus

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 17, 2022

                          Lead Product(s) : ABV-1701,Adipic Dihydrazide

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Vitargus (Hyaluronic Acid Derived Therapy) is a next-generation vitreous substitute that a First-In-Human clinical trial has demonstrated is a significant upgrade to current vitreous substitutes available to eye surgeons.

                          Product Name : Vitargus

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 09, 2022

                          Lead Product(s) : ABV-1701,Adipic Dihydrazide

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Vitargus/ABV-1701 (hyaluronic acid derived therapy) is a next-generation vitreous substitute that a First-In-Human clinical trial has demonstrated is a significant upgrade to current vitreous substitutes available to eye surgeons.

                          Product Name : Vitargus

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 30, 2022

                          Lead Product(s) : ABV-1701,Adipic Dihydrazide

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : ABV-1701 is an injectable, in-situ-forming hydrogel, composed of oxidized hyaluronic acid (oxi-HA) and adipic acid dihydrazide (ADH) and is used for the treatment of uncomplicated retinal detachment.

                          Product Name : Vitargus

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 10, 2022

                          Lead Product(s) : ABV-1701,Adipic Dihydrazide

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank